NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for nuvasive
73.89
+0.33 (0.45%)
Real-time:   2:07PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 72.97 - 74.04
52 week 38.46 - 75.10
Open 73.57
Vol / Avg. 279,795.00/544,615.00
Mkt cap 3.72B
P/E 107.82
Div/yield     -
EPS 0.69
Shares 50.60M
Beta 0.86
Inst. own 110%
Feb 9, 2017
Q4 2016 NuVasive Inc Earnings Release (Estimated)
Jan 9, 2017
NuVasive Inc at JPMorgan Healthcare Conference
Nov 29, 2016
NuVasive Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 2.20% 3.68%
Operating margin 11.09% 12.84%
EBITD margin - 20.90%
Return on average assets 1.49% 2.47%
Return on average equity 3.62% 5.28%
Employees 2,200 -
CDP Score - -

Address

7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Officers and directors

Gregory T. Lucier Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Jason M. Hannon President, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link President - U.S. Commercial
Age: 41
Bio & Compensation  - Reuters
Patrick W. G. Miles Vice Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer, Executive Vice President
Age: 37
Bio & Compensation  - Reuters
Joan B. Stafslien Executive Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Carol A. Cox Executive Vice President - External Affairs and Corporate Marketing
Age: 51
Bio & Compensation  - Reuters
Jason D. Hanson Executive Vice President - Strategy, Corporate Development and General Counsel
Age: 47
Bio & Compensation  - Reuters
Peter Michael Leddy Ph.D. Executive Vice President - Corporate Integrity and Global Human Resources
Age: 53
Bio & Compensation  - Reuters
Jack R. Blair Independent Director
Age: 73
Bio & Compensation  - Reuters